Research Article
Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
Table 1
Combination of DAAs and treatment according to genotype and DAA availability.
| HCV genotype | | DAA combination | Duration (weeks) |
| 1 | 7 | Sofosbuvir + Ribavirin | 24 | 8 | Ledipasvir + Sofosbuvir | 12 |
| 3 | 23 | Sofosbuvir + Ribavirin | 24 | 7 | Daclatasvir + Sofosbuvir | 12 (24 in cirrhotic; ) |
|
|